Compare JVA & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | CMMB |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Israel |
| Employees | 92 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4M | 20.5M |
| IPO Year | 1997 | 2023 |
| Metric | JVA | CMMB |
|---|---|---|
| Price | $4.63 | $1.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 76.6K | ★ 138.9K |
| Earning Date | 09-11-2026 | 11-19-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | ★ 0.68 | 0.04 |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.81 | $34.50 |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $1.05 |
| 52 Week High | $5.03 | $3.50 |
| Indicator | JVA | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 67.92 | 32.61 |
| Support Level | $4.15 | $1.05 |
| Resistance Level | $4.59 | $1.83 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 79.16 | 27.15 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.